Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behçet's Disease

Sayarlıoğlu, Mehmet; Kotan, Mehmet Çetin; Topcu, Nazan; Bayram, İrfan; Arslantürk, Hasan; Gül, Ahmet

doi:10.1345/aph.1d524

Cited by 34 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Substantial evidences show a pivotal role for proinflammatory Cytokines (e.g., interleukin1, interleukin6, and tumor necrosis factor-␣) in induction of CNS mediated responses such as fever, somnolence, and sickness behavior in acute infections. 4 We suggest that these drugs, which are approved by FDA for some of the aforementioned diseases, can be useful in treating patients with chronic fatigue syndrome. 2 Recently, biological agents that bind and neutralize the tumor necrosis factor have become available: 1) Etanercept, a tumor necrosis factor type 2 receptor fused to IgG1, is assessed to be effective in psoriasis.…”

Section: Potential Drugs For Improving Chronic Fatigue Syndromementioning

confidence: 99%

Cilostazol, a cAMP Phosphodiesterase 3 Inhibitor, in the Treatment of Poststroke Depression

Nishimura¹,

Ishigooka²,

Imamura³

et al. 2007

JNP

View full text Add to dashboard Cite

Section: Potential Drugs For Improving Chronic Fatigue Syndromementioning

confidence: 99%

Cilostazol, a cAMP Phosphodiesterase 3 Inhibitor, in the Treatment of Poststroke Depression

Nishimura¹,

Ishigooka²,

Imamura³

et al. 2007

JNP

View full text Add to dashboard Cite

“…Although clinical evidence is lacking, thalidomide and its analog lenalidomide are sometimes used for the management of CD,262728 and there are several studies that report the efficacy of thalidomide in intestinal BD 2930313233. Travis et al29 reported that thalidomide was used for maintenance therapy in patients treated with IFX.…”

Section: Medical Treatmentmentioning

confidence: 99%

“…In a report by Kari et al,31 5 pediatric BD patients were treated with thalidomide at 1 mg/kg/wk to 1 mg/kg/day, resulting in complete remission in 3 patients and clinical response in 2. Sayarlioglu et al32 reported a patient who required multiple surgeries due to intestinal perforations and was refractory to intense immunosuppressive therapies, including methylprednisolone and cyclophosphamide. Thalidomide (100 mg/day) was started after the third surgery, and the patient experienced no additional intestinal perforations during the follow-up period of 4 months.…”

Section: Medical Treatmentmentioning

confidence: 99%

“…In contrast, Choi et al22 reported that patients who received azathioprine postoperatively showed better clinical courses than those who did not. Thalidomide was also used as a postoperative therapy in a patient who required multiple surgeries 32. To date, there are no reports reviewing the efficacy of postoperative anti-TNF-α mAbs therapy in intestinal BD patients.…”

Section: Surgical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease

Hisamatsu

Hayashida

2017

Intest Res

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions may be a poor prognostic factor in intestinal BD, increasing the risk of surgery and decreasing the quality of life. Despite this, the management of intestinal BD has not been standardized. Empirical therapies including 5-aminosalicylic acid and corticosteroids have been used anecdotally to treat intestinal BD, but recent studies have provided evidence for the efficacy of anti-tumor necrosis factor α monoclonal antibodies. The development of agents targeting tumor necrosis factor α continues, it seems likely that they will change the therapeutic strategy and clinical outcomes of intestinal BD and inflammatory bowel disease. Monitoring disease activity such as endoscopic evaluation will become more important to obtain better outcomes. Here, we review current and future perspectives in the treatment and outcomes of intestinal BD.

show abstract

“…The use of the drug was associated with an increase in erythema nodosum in the first 8 weeks of the study. Four patients developed polyneuropathy as complication of the treatment [72]. In another prospective study, 23 patients with BD and severe refractory oral or genital ulceration were treated with thalidomide.…”

Section: Thalidomidementioning

confidence: 99%

Update on the Therapy of Behçets Disease

Arayssi¹

2005

CMCAIAA

View full text Add to dashboard Cite

Behçet's disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The prevalence of BD is highest in the Middle East, Mediterranean region and Asia. The usual age of onset is around 30, and the male to female ratio varies with the ethnic background. The cause of BD remains unknown. It is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. The main objectives of therapy of BD are to relieve its symptoms, decrease recurrences and prevent irreversible damage. This choice, however, is limited by the paucity of high quality therapy trials. Therapy studies for this disease in general, lack high methodological quality and common outcome measures, making treatment of this disease for the most part empirical. Most randomized studies have focused on the treatment of ocular, mucocutaneous and musculoskeletal diseases, while data on the treatment of the other manifestations is based on uncontrolled data.

show abstract

Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behçet's Disease

Abstract: Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.

Cited by 34 publications

References 22 publications

Cilostazol, a cAMP Phosphodiesterase 3 Inhibitor, in the Treatment of Poststroke Depression

Cilostazol, a cAMP Phosphodiesterase 3 Inhibitor, in the Treatment of Poststroke Depression

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease

Update on the Therapy of Behçets Disease

Contact Info

Product

Resources

About